EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Outcomes and Prognostic Implications of TAVR in Patients With Active Cancer: A Meta‐Analysis

Parsa Saberian, Rafael Contreras, Anoop Gurram, Amir Nasrollahizadeh, Narsimha Rao Keetha, Anthony Loc Nguyen, Sandeep Samethadka Nayak, Mohammad-Hossein Keivanlou, Mohammad Hashemi, Ehsan Amini-Salehi, Daniyal Ameen

Clinical Cardiology · 2025

DOI: 10.1002/clc.70121 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Parsa Saberian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Neoplasms, Aortic Valve. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement (SAVR) for high‐risk patients with severe aortic stenosis (AS). However, the clinical outcomes and prognostic implications of TAVR in patients with active cancer remain uncertain. This meta‐analysis evaluates procedural success, complications, and survival outcomes of TAVR in patients with and without active cancer.

Methods

A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science databases. Statistical analysis was performed using a random‐effects model. Statistical analyses were conducted using STATA version 18.0.

Results

The results of the meta‐analysis showed no significant difference in in‐hospital mortality between cancer and non‐cancer patients (OR = 1.17; 95% CI: 0.83, 1.65; p = 0.27). Similarly, 30‐day mortality did not differ between the two groups (OR = 0.93; 95% CI: 0.72, 1.19; p = 0.49). However, 1‐year mortality was significantly higher in cancer patients (OR = 1.93; 95% CI: 1.45, 2.56; p < 0.01). Two‐year mortality was also higher in cancer patients (OR = 2.65; 95% CI: 1.79, 3.93; p < 0.01). No significant differences were observed in major bleeding, acute kidney injury, stroke, or permanent pacemaker implantation between the groups.

Conclusion

While TAVR offers comparable in‐hospital and short‐term survival outcomes for cancer and non‐cancer patients, long‐term mortality is significantly higher in those with active cancer. These findings suggest that TAVR is a viable option for cancer patients with severe AS but requires careful long‐term prognostic considerations. Further studies are needed to optimize management strategies for this complex population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisNeoplasmsAortic ValveHumansTreatment OutcomeRisk FactorsHospital MortalityPrognosisSurvival RateRisk AssessmentPostoperative ComplicationsGlobal HealthSeverity of Illness Index

Stichwörter der Autor:innen

TAVRcancercomplicationsmeta‐analysismortalityprognosis

Autor:innen und Institutionen

  • Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
  • Department of Internal Medicine, Yale New Heaven Health Bridgeport Hospital 267 Grant St, Bridgeport, CT, USA.
  • Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Ohio Kidney and Hypertension Center 7255, Middleburg Hts, OH, USA.
  • Division of Hematology/Oncology, Department of Internal Medicine, UC San Diego Health Moores Cancer Center, San Diego, CA, USA.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Saberian, P., Contreras, R., Gurram, A., Nasrollahizadeh, A., Keetha, N. R., Nguyen, A. L., Nayak, S. S., Keivanlou, M. H., Hashemi, M., Amini-Salehi, E., & Ameen, D. (2025). Clinical Outcomes and Prognostic Implications of TAVR in Patients With Active Cancer: A Meta‐Analysis. Clinical Cardiology. https://doi.org/10.1002/clc.70121

Vancouver

Saberian P, Contreras R, Gurram A, Nasrollahizadeh A, Keetha NR, Nguyen AL, et al. Clinical Outcomes and Prognostic Implications of TAVR in Patients With Active Cancer: A Meta‐Analysis. Clinical Cardiology. 2025. doi:10.1002/clc.70121

BibTeX
@article{Saberian2025,
  author = {Saberian, Parsa and Contreras, Rafael and Gurram, Anoop and Nasrollahizadeh, Amir and Keetha, Narsimha Rao and Nguyen, Anthony Loc and Nayak, Sandeep Samethadka and Keivanlou, Mohammad-Hossein and Hashemi, Mohammad and Amini-Salehi, Ehsan and Ameen, Daniyal},
  title = {Clinical Outcomes and Prognostic Implications of TAVR in Patients With Active Cancer: A Meta‐Analysis},
  journal = {Clinical Cardiology},
  year = {2025},
  doi = {10.1002/clc.70121}
}
Kostenlos starten →